The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Tumor Markers in the Diagnosis of Primary Bladder Cancer. A Systematic Review
Abstract
PURPOSE: We systematically reviewed the available evidence, and obtained and compared summary estimates of the sensitivity and specificity of cytology and the urine based markers bladder tumor antigen, BTA stat (Polymedco, Redmond, Washington), BTA TRAK (Polymedco), NMP22 (Matritech, Cambridge, Massachusetts), telomerase and fibrin degradation product in detecting primary bladder cancer. MATERIALS AND METHODS: Studies on the diagnosis of primary bladder cancer published from 1990 through November 2001 in English and German were retrieved from MEDLINE and EMBASE data bases. In our research we included studies that evaluated 1 or more of the markers, used cystoscopy as the reference standard and allowed the construction of a 2 x 2 contingency table for a per patient analysis. The data plus items on study and clinical characteristics were extracted by 2 observers. Sensitivity and specificity for each marker were estimated using a bivariate random effect meta-analysis. A multivariable analysis was performed to explain study variation. RESULTS: A total of 42 studies were included in our review. Only 2 studies were available on fibrin degradation product, hence a meta-analysis was not possible. Cytology had the best specificity at 94% (95% CI: 90% to 96%). This figure was significantly better than that of the other markers except for telomerase (specificity 86% [71% to 94%]). Telomerase had the best sensitivity (75% [71% to 79%]) but it was not significantly better than that of BTA stat (70% [66% to 74%]). Case control designs yielded lower values for sensitivity for the tumor markers cytology, bladder tumor antigen and BTA stat. CONCLUSIONS: Cytology has the best specificity and telomerase the best sensitivity. However, none of the markers studied here is sensitive enough to be recommended for daily routine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of the worldwide incidence of 25 major cancers in 1990
Parkin, Pisani, P., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>3.0.co;2-p · Cited by 2,037
Empirical evidence of design-related bias in studies of diagnostic tests.
Lijmer, J. G. (1999) · JAMA · doi:10.1001/jama.282.11.1061 · Cited by 1,861
Problems of Spectrum and Bias in Evaluating the Efficacy of Diagnostic Tests
Ransohoff, D. F., & Feinstein, A. R. (1978) · New England Journal of Medicine · doi:10.1056/nejm197810262991705 · Cited by 1,734
Advanced methods in meta‐analysis: multivariate approach and meta‐regression
van Houwelingen, H. C., Arends, L. R., & Stijnen, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1040 · Cited by 1,580
Evidence base of clinical diagnosis: The architecture of diagnostic research
Sackett, D. L. (2002) · BMJ · doi:10.1136/bmj.324.7336.539 · Cited by 724
Use of methodological standards in diagnostic test research. Getting better but still not good
Reid, M. C. (1995) · JAMA · doi:10.1001/jama.274.8.645 · Cited by 712
The uncertainty principle and industry-sponsored research
Djulbegovic, B., Lacevic, M., Cantor, A., Fields, K. K., Bennett, C. L., Adams, J. R., Kuderer, N. M., & Lyman, G. H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02605-2 · Cited by 482
Estimating Diagnostic Accuracy from Multiple Conflicting Reports: A New Meta-analytic Method
Littenberg, B., & Moses, L. E. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300408 · Cited by 434
COMPARISON OF SCREENING METHODS IN THE DETECTION OF BLADDER CANCER
RAMAKUMAR, S., BHUIYAN, J., BESSE, J. A., ROBERTS, S. G., WOLLAN, P. C., BLUTE, M. L., & O'KANE, D. J. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61899-8 · Cited by 335
Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer
Landman, J., Chang, Y., Kavaler, E., Droller, M. J., & Liu, B. C.-S. (1998) · Urology · doi:10.1016/s0090-4295(98)00219-2 · Cited by 239
Cited by
Reitsma, J. B., Glas, A. S., Rutjes, A. W. S., Scholten, R. J. P. M., Bossuyt, P. M., & Zwinderman, A. H. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.02.022 · Cited by 3,369
Self-citationSystematic reviews: CRD's guidance for undertaking reviews in health care
Tacconelli, E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70065-7 · Cited by 3,245
Systematic Reviews of Diagnostic Test Accuracy
Leeflang, M. M. G., Deeks, J. J., Gatsonis, C., & Bossuyt, P. M. M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-12-200812160-00008 · Cited by 1,124
Self-citationUrine Markers for Bladder Cancer Surveillance: A Systematic Review
van Rhijn, B. W. G., van der Poel, H. G., & van der Kwast, T. H. (2005) · European Urology · doi:10.1016/j.eururo.2005.03.014 · Cited by 530
Case–Control and Two-Gate Designs in Diagnostic Accuracy Studies
Rutjes, A. W., Reitsma, J. B., Vandenbroucke, J. P., Glas, A. S., & Bossuyt, P. M. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.048595 · Cited by 501
Self-citation
Metadata
- Authors
- GLAS, A. S., ROOS, D., DEUTEKOM, M., ZWINDERMAN, A. H., BOSSUYT, P. M. M., & KURTH, K. H.
- Venue
- Journal of Urology
- Published
- 2003-06
- Volume
- 169
- Issue
- 6
- Pages
- 1975-1982
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2006723863
- Cited by
- 268
- References
- 28
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor Markers in the Diagnosis of Primary Bladder Cancer. A Systematic Review. https://app.cochat.ai/papers/10.1097/01.ju.0000067461.30468.6d
- The paper
- GLAS, A. S., ROOS, D., DEUTEKOM, M., ZWINDERMAN, A. H., BOSSUYT, P. M. M., & KURTH, K. H. (2003). Tumor Markers in the Diagnosis of Primary Bladder Cancer. A Systematic Review. Journal of Urology. https://doi.org/10.1097/01.ju.0000067461.30468.6d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.